Clinical trials: BCC
Basal Cell Carcinomas
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
- Trial name
- NCT02067104
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Skin Cancer, Squamous Cell Carcinoma
Skin Tumor Biomarkers by Mass Spectrometry Imaging
The purpose of the study is to investigate the ability of mass spectrometry imaging to locate aggregates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) ex-vivo, and to distinguish areas containing these…
- Conditions
- Skin Cancer, Squamous Cell Carcinoma, Basal Cell Carcinoma, Non-melanoma Skin Cancer
- Trial name
- NCT06227416
- Testing
- Biopsy
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Bispebjerg Hospital
Basal Cell Carcinoma
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
This is a phase 2 trial assessing the efficacy of nivolumab, alone or in combination with relatlimab or ipilimumab in treating patients with locally-advanced unresectable or metastatic basal cell carcinoma.
- Trial name
- NCT03521830
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Basal Cell Carcinomas
Transcriptomic Analysis and Optical Coherence Tomography Combined for Patients With Basal Cell Carcinoma
The goal of this observational study is to learn if tape strip for transcriptomic (RNA) analysis and optical coherence tomography (OCT) combined can optimize noninvasive management of basal cell carcinoma (BCC) patients.
- Trial name
- RNA-OCT-BCC (NCT06813833)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Bispebjerg Hospital
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Skin Neoplasm, Squamous Cell Carcinoma
Utility of the Skin Cancer Quality of Life Impact Tool
Background: Patient-reported outcome measures (PROMs) provide validated evidence of health and quality of life (QoL) from the patient perspective.
- Conditions
- Skin Neoplasm, Squamous Cell Carcinoma, Basal Cell Carcinoma
- Trial name
- SCQOLIT (NCT02580916)
- Testing
- SCQOLIT questionnaire
- Where
- United Kingdom
- Volunteers
- 318 people
- Sponsor
- Oxford University Hospitals NHS Trust
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.
- Trial name
- NCT05157763
- Testing
- EscharEx 5% (EX-02 formulation)
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediWound Ltd
Basal Cell Carcinoma
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472043
- Testing
- PDT with Metvix 160 mg/g cream
- Where
- 7 sites in Australia
- Volunteers
- 66 people
- Sponsor
- Galderma R&D
Basal Cell Carcinoma
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells.
- Trial name
- NCT00473343
- Testing
- Metvix® cream
- Where
- 7 sites in Australia
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Basal Cell Carcinoma, Squamous Cell Carcinoma
Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?
The investigators hypothesize that everting wound edges while suturing surgical sites will result in more aesthetic scars. Additionally, we also hypothesize that small to moderate wound irregularities present at 3 months will…
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT01770002
- Testing
- Everted suture technique, Non-everted suture technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Davis
Skin Cancer
Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation.
- Trial name
- NCT01345760
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Lymphoma, Non-melanomatous Skin Cancer
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Conditions
- Lymphoma, Non-melanomatous Skin Cancer, Precancerous Condition
- Trial name
- NCT00103246
- Testing
- silicon phthalocyanine 4
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Basal Cell Carcinoma, Radiotherapy; Complications
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy.
- Trial name
- RADIOSONIC (NCT05561634)
- Testing
- Radiotherapy, Observation, Vismodegib
- Where
- France
- Volunteers
- 82 people
- Sponsor
- University Hospital, Lille
Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma
Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis.
- Conditions
- Basal Cell Carcinoma of Skin, Site Unspecified, Epidermoid Carcinoma, Lynch Syndrome, Muir-Torre Syndrome
- Trial name
- SMT-SL (NCT07201012)
- Testing
- Sampling of suspected skin lesions (in accordance with good care practices)., Constitution of a biobank
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Skin Cancer Excision Site, Basal Cell Carcinoma
Impact of Dysport on PMFF Donor Scar
The purpose of this research study is to investigate the effect of pre-operative injections of Dysport (Abobotulinumtoxin-A, commonly known as "Botox") on the cosmetic appearance of and overall satisfaction with study…
- Conditions
- Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT07720726
- Testing
- Abobotulinumtoxin-A, Control- Saline injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vanderbilt University Medical Center
Locally Advanced Basal Cell Carcinoma, Skin Cancer
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and…
- Conditions
- Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
- Trial name
- NCT01835626
- Testing
- Vismodegib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sue Yom
Basal Cell Nevus Syndrome
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Multicenter, double-blind, randomized, vehicle-controlled study that evaluates the efficacy and safety of patidegib gel 2% and 4% in comparison with vehicle in participants at least 18 years of age that meet the diagnostic…
- Trial name
- NCT02762084
- Testing
- Patidegib, Vehicle gel
- Where
- 2 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- PellePharm, Inc.
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
The primary objectives are to: 1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s; 2.
- Trial name
- NCT04416516
- Testing
- ASN-002
- Where
- 7 sites in Australia
- Volunteers
- 21 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Locally Advanced Basal Cell Carcinoma
A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC.
- Trial name
- NCT07808515
- Testing
- Cemiplimab, Vidutolimod, Fianlimab
- Volunteers
- 135 people
- Sponsor
- Regeneron Pharmaceuticals
Basal Cell Carcinoma, Squamous Cell Carcinoma
Study Assessing the Safety and Performance of Smart Matrix®
Smart Matrix is a sterile, single layer dermal replacement scaffold. The scaffold consists of a porous matrix of cross-linked human fibrin plus alginate that has been designed and optimised to facilitate wound closure and healing…
- Trial name
- NCT03742726
- Testing
- Smart Matrix scaffold
- Where
- 4 sites in United Kingdom
- Volunteers
- 32 people
- Sponsor
- Smart Matrix Limited